These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9753967)

  • 1. [Anesthesia for a patient with von Willebrand disease and asthma].
    Ehata T; Karasawa F; Satoh T
    Masui; 1998 Aug; 47(8):992-4. PubMed ID: 9753967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urgent hemostatic control with Confact F for ovarian bleeding complicated by an unknown type of von Willebrand disease].
    Suzuki T; Kagawa K; Oishi T; Kawata K; Fujito A; Isaka K; Fukutake K
    Rinsho Ketsueki; 2008 Dec; 49(12):1623-7. PubMed ID: 19110525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients].
    Kurth AA; Ludwig G; Scharrer I
    Orthopade; 1999 Apr; 28(4):366-74. PubMed ID: 10335531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Perioperative management of the patient with von Willebrand's disease].
    Nishimori T; Kohchi A; Hasegawa R
    Masui; 2001 Sep; 50(9):1012-5. PubMed ID: 11593712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anesthetic management of cesarean section in a patient with type II von Willebrand disease].
    Ito H; Satoh M; Seo N
    Masui; 2008 Feb; 57(2):203-5. PubMed ID: 18277572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis and von Willebrand's disease (vWD).
    Abshire TC
    Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
    Coppola A; Cimino E; Conca P; De Simone C; Tufano A; Tarantino G; Cerbone AM; Minno G
    Haemophilia; 2006 Jan; 12(1):90-4. PubMed ID: 16409182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
    Cattaneo M; Federici AB; Lecchi A; Agati B; Lombardi R; Stabile F; Bucciarelli P
    Thromb Haemost; 1999 Jul; 82(1):35-9. PubMed ID: 10456451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.